Abstract
Global Pneumococcal Disease and Policies for Control
Highlights
Cost-effectiveness analyses (CEAs) of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10, PCV13) have been based on extrapolation of efficacy and effectiveness data from the 7-valent vaccine (PCV7)
The numbers of HIV-exposed children infected annually continue to drop due to improvements in prevention of mother-to-child transmission (PMTCT); we have shown that these exposed but uninfected children are at increased risk of invasive pneumococcal disease (IPD) and mortality compared with HIV-unexposed children
We systematically searched literature and national surveillance databases from 1980-2010 for agestratified (5-19, 20-64, ≥65 years) pneumococcal meningitis incidence and inputs for two indirect estimation approaches: invasive pneumococcal disease (IPD) incidence multiplied by proportion of IPD that is meningitis and all-cause bacterial (AB) meningitis incidence multiplied by proportion of AB meningitis due to pneumococcus for persons >5 years
Summary
Cost-effectiveness analyses (CEAs) of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10, PCV13) have been based on extrapolation of efficacy and effectiveness data from the 7-valent vaccine (PCV7). Methods: We conducted a cohort surveillance study in children
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.